Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of VUM02 Injection in the Treatment of Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD)

NCT06677255 is registered in ClinicalTrials.gov with Wuhan Optics Valley Vcanbiopharma Co., Ltd. as lead sponsor.

NCT NCT06677255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06677255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of VUM02 Injection in the Treatment of Patients With Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD)
Lead sponsor
Wuhan Optics Valley Vcanbiopharma Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 31, 2025
Completion date
December 31, 2028
Enrollment
149 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

steroid-refractory acute graft-versus-host disease